Cost-benefit analysis of an intensive adverse product reactions monitoring program of inpatients in Thailand.
The objective of this study was to analyze the costs and benefits of the intensive adverse products reactions (APRs) monitoring program of inpatients in medical wards at Nakhon Ping Hospital, Chiang Mai, Thailand. The data were retrospectively collected from inpatients who had APRs during admission period from November 16, 2004 to March 31, 2005. Products included were drugs, electrolyte solutions, bloods and blood derivatives. Only direct medical costs were considered using provider's perspective. The results showed that there were 1,407 admitted patients during the study period. Adverse products reactions were found in 31 patients. Of those, three patients had two APRs. Therefore, a total of 34 APRs were found yielding the APRs incidence rate of 24 per 1,000 inpatients. Of the APRs found, 20 were reported after the symptoms had begun, but the remaining APRs were preventable. Drugs were the main causes for APRs (94.12%). Cost of intensive APRs monitoring was 1,426.37 US dollars and included 939.44 US dollars for labor costs, 12.5 US dollars for material costs, 29.07 US dollars for capital cost and 445.36 US dollars for APRs treatment and investigation. The program cost saving excluding the cost of hemodialysis was 3,090.85 US dollars. Net benefit was 1,664.48 US dollars and benefit to cost (B/ C) ratio was 2.17. When one time hemodialysis cost was included, cost saving increased to 4,040.85 US dollars. Net benefit and B/C ratio were 2,614.48 US dollars and 2.84 respectively. The results of sensitivity analysis represented that net benefit and B/C ratio were increased when duration of digoxin intoxication was prolonged. However, net benefit and B/C ratio were decreased when pharmacist labor cost was increased. Results indicate that intensive APR monitoring is a cost beneficial program and should be continuously implemented.
Tasila
Janejira
J
Pharmacy Department, Chiang Kham Hospital, Phayao, Thailand.
Permsuwan
Unchalee
U
D016907:Adverse Drug Reaction Reporting Systems / Q000191:economics*; D003362:Cost-Benefit Analysis; D007297:Inpatients / Q000706:statistics & numerical data*; D015397:Program Evaluation / Q000191:economics*; D012680:Sensitivity and Specificity; D013785:Thailand